OpenAI Foundation commits $1B to cure diseases and study AI risks

When OpenAI underwent its massive corporate recapitalization last fall, skeptics wondered what would happen to its non-profit roots. Now, we have an answer with a ten-figure price tag.

Bret Taylor, chair of the OpenAI Foundation, announced that the organization plans to deploy at least $1 billion over the next year across life sciences, jobs and economic impact, AI resilience, and community programs.

This $1 billion represents the first major rollout of a previously announced $25 billion commitment aimed at curing diseases and addressing AI-driven societal risks.

Curing diseases and boxing in rogue biology

The foundation is setting up distinct focus areas led by heavy hitters from both OpenAI and the philanthropic sector.

On the healthcare front, the initiative has been rebranded to Life Sciences, led by Jacob Trefethen, formerly of Coefficient Giving where he oversaw $500 million in science grants. Their first target is Alzheimer’s disease, where they plan to use AI reasoning models to map disease pathways, pinpoint clinical biomarkers, and repurpose existing FDA-approved drugs.

They also plan to build open, high-quality health datasets, unlocking previously restricted data so outside researchers can train models without massive corporate budgets.

On the defensive side, OpenAI co-founder Wojciech Zaremba is taking charge of AI Resilience. His team will tackle three pressing issues: child and youth safety, biosecurity threats (both natural and AI-augmented), and funding independent model safety evaluations.

To manage this operation, former Twitter and Deloitte executive Robert Kaiden has stepped in as CFO, while former OpenAI VP of Global Impact Anna Makanju will lead civil society efforts starting in mid-April. The board is still hunting for an Executive Director.

Why it matters

We think this move is as much about corporate legitimacy as it is about philanthropy.

As OpenAI commercializes its frontier models, critics have argued that the non-profit mission got left in the dust. Committing $1 billion right out of the gate is a calculated push to prove the Foundation still has teeth, deep pockets, and independence.

For the scientific community, the most valuable piece here isn't necessarily the cash, but the data. Health tech often hits a wall not because algorithms fail, but because clinical datasets are locked behind commercial paywalls. If OpenAI can responsibly open up high-quality medical databases, it gives academic labs an unprecedented boost.

The catch? A billion dollars gets burned through fast in clinical biotech, and Alzheimer's remains a notorious graveyard for medical breakthroughs. Still, seeing frontier AI profits funnel back into biosecurity and open science is a blueprint competitors will likely have to match.